Prostate Cell News Volume 4.05 | Feb 8 2013

LABORATORY RESEARCH

Type 10 Soluble Adenylyl Cyclase Is Overexpressed in Prostate Carcinoma and Controls Proliferation of Prostate Cancer Cells
Significant overexpression of soluble adenylyl cyclase, an alternative source of cyclic AMP, was found in human prostate carcinoma, and therefore, the contribution of this cyclase was investigated in the prostate carcinoma cell lines LNCaP and PC3. [J Biol Chem] Abstract | Press Release

Role of WNT7B-Induced Non-Canonical Pathway in Advanced Prostate Cancer
Investigators identified WNT7B as a direct androgen receptor target gene highly expressed in castration-resistant prostate cancer cells. [Mol Cancer Res] Abstract

Differential Signaling of the GnRH Receptor in Pituitary Gonadotrope Cell Lines and Prostate Cancer Cell Lines
The GnRH receptor (GnRHR) mediates the pituitary functions of GnRH, as well as its anti-proliferative effects in sex hormone-dependent cancer cells. The authors compared the signaling of GnRHR in pituitary gonadotrope cell lines vs. prostate cancer cell lines. [Mol Cell Endocrinol] Abstract

Human Prostate Side Population Cells Demonstrate Stem Cell Properties in Recombination with Urogenital Sinus Mesenchyme
Scientists isolated and analyzed cells digested from twelve clinical prostate specimens based on the side population assay. Prostate stem cell properties of the isolated cells were tested by serial recombination with rat urogenital mesenchyme. [PLoS One] Full Article

MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer
Researchers found that microRNA (miR)-182-5p expression was significantly higher in prostate cancer tissues and cell lines compared to normal prostate tissues and cells. Moreover, high miR-182-5p expression was associated with shorter overall survival in prostate cancer patients. [PLoS One] Full Article

Androgen Up-Regulates Vascular Endothelial Growth Factor Expression in Prostate Cancer Cells via an Sp1 Binding Site
Three novel androgen receptor (AR) binding sites were discovered in the Vascular Endothelial Growth Factor promoter and in vivo binding of AR to these sites was demonstrated by chromatin immunoprecipitation. [Mol Cancer] Abstract | Full Article

Up-Regulated MicroRNA-143 in Cancer Stem Cells Differentiation Promotes Prostate Cancer Cells Metastasis by Modulating Fibronectin Type III Domain Containing 3B Expression
The expression of microRNA (miR)-143 and the migration capability were reduced in PC-3 sphere cells and progressively increased during sphere re-adherent culture. The down-regulation of miR-143 suppressed prostate cancer cells migration and invasion in vitro and systemically inhibited metastasis in vivo. [BMC Cancer] Abstract | Full Article

CLINICAL RESEARCH

Short-Term versus Long-Term Hormone Therapy Plus Radiotherapy or Prostatectomy for Prostate Cancer: A Systematic Review and Meta-Analysis
The authors compared the efficacy and safety of short-term versus long-term hormonotherapy plus radiotherapy or prostatectomy for prostate cancer. [J Cancer Res Clin] Abstract

Phase III, Randomized, Placebo-Controlled Study of Once-Daily Oral Zibotentan (ZD4054) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
This study, part of the ENTHUSE (EndoTHelin A USE) Phase III programme, evaluated the efficacy and safety of the oral specific endothelin-A receptor antagonist zibotentan vs placebo in patients with non-metastatic castration-resistant prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

True Diagnostics Receives CE Mark for Quantitative PSA Test
True Diagnostics, Inc.™ announced it has received a CE Mark for TrueDX™PSA, its quantitative PSA (Prostate Specific Hormone) test. With the TrueDX™PSA Test doctors can immediately determine the PSA level in a patient with only a finger prick of blood – rather than wait days for lab results from an intravenous blood draw. [True Diagnostics, Inc.™] Press Release

Aduro Announces Acquisition of GVAX Assets From BioSante
Aduro BioTech, Inc. announced the acquisition of all GVAX assets from BioSante Pharmaceuticals, Inc., including intellectual property and cell lines. Aduro previously licensed two GVAX vaccines, GVAX Pancreas and GVAX Prostate, for use in combination with its Listeria-based vaccines. This new acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancer and assumes rights to the existing license agreement for GVAX Melanoma. [Business Wire] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Healthcare Education Services’ Introduction to Oncology and Chemotherapy Course
May 22-23, 2013
Newark, United States

Visit our events page to see a complete list of events in the prostate cell community.

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

PhD Studentship – Genome Mutation Data for the Clinical Management of Patients with Prostate Cancer (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – The Role of ABC Transporter in Prostate Cancer (Queen Mary University London)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.